Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi Buys Abgent, a US-China Antibody Maker

publication date: Oct 14, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech, a leading China CRO, has acquired Abgent, Inc., a provider of antibodies and custom services based in Suzhou and San Diego. The price was not disclosed. Because Abgent is a well-established antibody manufacturer, the transaction underscores the growing importance of biologics to WuXi’s business. Dr. Ge Li, Chairman and CEO of WuXi characterized the acquisition as “small but strategically important.” More details....

Stock Symbol: (NYSE: WX)

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors